Georgia's Online Cancer Information Center

Hematopoietic Malignancies Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Hematopoietic Malignancies
Cancer Type = Hematopoietic Malignancies
There are currently 78 active Hematopoietic Malignancies clinical trials in Georgia.
1.
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03731260
Protocol IDs
BLU-285-2203
NCI-2019-01095
2018-000588-99
2.
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Neuroblastoma
NCT ID
NCT04239092
Protocol IDs
1902
NCI-2020-04584
3.
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04115631
Protocol IDs
EA4181
EA4181
NCI-2019-05536
Treatment Sites (2)
4.
NCORP Trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT01351545
Protocol IDs
10-CBA
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) (FIRM)
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT02694978
Protocol IDs
AMAG-FER-IDA-304
6.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04409301
Protocol IDs
AFLAC4875-19
NCI-2019-08591
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
8.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
NCI-2020-04370
2019-001937-16
AUTO1-AL1
9.
NCORP Trial
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Bile Duct Cancer, Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03329950
Protocol IDs
CDX1140-01
NCI-2018-00959
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
10.
A Study of CPI-0209 in Patients With Advanced Tumors
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
11.
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03372057
Protocol IDs
VS-0145-225
NCI-2018-00275
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
13.
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03323151
Protocol IDs
PrE0404
NCI-2017-02399
X16077
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
15.
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03078855
Protocol IDs
66593
NCI-2018-00258
R01CA214890
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCT ID
NCT03011372
Protocol IDs
INCB 54828-203
NCI-2017-00141
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04196491
Protocol IDs
BB2121-MM-004
NCI-2020-00209
U1111-1243-5088
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
18.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03391778
Protocol IDs
208750
NCI-2018-01288
ADP-0000-002
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
20.
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Cancer Type
COVID-19, Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04659135
Protocol IDs
Pro00014181
NCI-2021-00737
21.
Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT02862275
Protocol IDs
10014
10014
NCI-2016-01232
PJC-023
Treatment Sites (3)
22.
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03564587
Protocol IDs
CHOA4223-17
NCI-2018-00736
IRB00099050
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
23.
Bendamustine, Obinutuzumab, and Venetoclax in Treating Patients with Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03872180
Protocol IDs
Winship4363-18
NCI-2018-00995
IRB00102827
Treatment Sites (3)
24.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
NCI-2013-01275
U10CA021115
E4412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT01499394
Protocol IDs
TCBIO-001-0710
Treatment Sites (1)
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
26.
NCORP Trial
Collection of Research Data and Samples from Patients Who Experience Immunotherapy Side Effects
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04242095
Protocol IDs
A151804
A151804
NCI-2019-07113
Treatment Sites (1)
27.
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCT ID
NCT03397706
Protocol IDs
VT3996-201
NCI-2018-00416
28.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
NCI-2017-01243
APEC1621F
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
29.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
30.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
31.
Faith-Based African American Cancer Survivorship Storytelling
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03082612
Protocol IDs
EU3999-17
NCI-2017-00980
IRB00093110
Treatment Sites (1)
32.
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT00785525
Protocol IDs
PBSC
NCI-2014-00012
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
Gemcitabine, Bendamustine Hydrochloride, and Nivolumab in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT03739619
Protocol IDs
Winship4388-18
NCI-2018-02221
IRB00104033
Treatment Sites (2)
34.
Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
35.
NCORP Trial
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02443077
Protocol IDs
A051301
NCI-2015-00668
BMT CTN 1201
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
36.
Imaging and Blood Biomarker Evaluation of Engraftment after Allogeneic Hematopoietic Stem Cell Transplant, REVEAL Study
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03541889
Protocol IDs
OUHSC4891-19
NCI-2020-13763
37.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
38.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
39.
Maintenance Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02498951
Protocol IDs
IRB00011601
NCI-2015-01014
ML29496
40.
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04762875
Protocol IDs
145-ADS-202
NCI-2021-03246
41.
Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04089358
Protocol IDs
ALTE2031
ALTE2031
COG-ALTE2031
NCI-2020-01916
42.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT01981187
Protocol IDs
CLGX818AUS03
Treatment Sites (1)
43.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04676087
Protocol IDs
WINSHIP5101-20
NCI-2020-06013
44.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Hematopoietic Malignancies, Lung Cancer, Multiple Myeloma, Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
45.
NCORP Trial
NCI COVID-19 in Cancer Patients, NCCAPS Study
Cancer Type
COVID-19, Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04387656
Protocol IDs
NCICOVID
NCICOVID
NCI-2020-02986
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
46.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
47.
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03816345
Protocol IDs
10204
10204
NCI-2019-00241
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
Nivolumab with or without Varlilumab in Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03038672
Protocol IDs
10089
10089
NCI-2017-00120
MC168D
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
49.
NCORP Trial
Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02992522
Protocol IDs
OSU-16187
NCI-2016-01723
2016C0150
Treatment Sites (1)
51.
Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03598998
Protocol IDs
17501
NCI-2018-01420
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04101331
Protocol IDs
AFM13-202
NCI-2019-07995
53.
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04665765
Protocol IDs
20148
NCI-2020-08524
54.
Predicting Childhood Cancer Survivors' Transition Readiness and Transfer Outcomes, SURV Transfer Outcomes Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04257058
Protocol IDs
CHOA4312-18
NCI-2020-07495
55.
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT02252159
Protocol IDs
INCB-MA-PV-401
56.
NCORP Trial
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT01166009
Protocol IDs
NMDP IRB-1999-0021
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
57.
Radiosurgery before Surgery for the Treatment of Brain Metastases
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04895592
Protocol IDs
RAD5234-21
NCI-2021-02761
STUDY00001896
58.
Rifaximin in Preventing Infections in Participants with Blood Cancer Undergoing Hematopoietic Stem Cell Transplantation
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT03529825
Protocol IDs
CHOA4273-18
NCI-2018-00596
IRB00101158
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
59.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
60.
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT02636855
Protocol IDs
ADP-0000-001
NCI-2016-01399
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
61.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders with Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT04320888
Protocol IDs
APEC1621N
APEC1621N
NCI-2020-01756
Treatment Sites (1)
62.
NCORP Trial
Smoke Free Support Study 2.0
Cancer Type
Hematopoietic Malignancies, Solid Tumor, Unknown Primary
NCT ID
NCT03808818
Protocol IDs
EAQ171CD
EAQ171CD
ECOG-ACRIN-EAQ171CD
NCI-2018-02826
63.
NCORP Trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02631044
Protocol IDs
017001
NCI-2016-00057
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
64.
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
65.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCT ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
66.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
67.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
68.
SurvivorLink in Improving Quality of Life in Cancer Survivors and Caregivers
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03543852
Protocol IDs
RSPH-AFLAC4297-18
NCI-2018-00396
IRB00101506
70.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03984448
Protocol IDs
A051701
A051701
NCI-2019-03711
Treatment Sites (2)
71.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
72.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
73.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
74.
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03570892
Protocol IDs
CCTL019H2301
NCI-2018-02925
2016-002966-29
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
75.
Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
76.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02495415
Protocol IDs
FEN T-14
NCI-2015-01195
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
78.
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04703192
Protocol IDs
DS3201-A-U202
NCI-2021-06342
2020-004954-31
jRCT2071200095
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.